Keybank National Association OH Has $245,000 Holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Keybank National Association OH cut its stake in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 27.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,793 shares of the medical device company’s stock after selling 2,615 shares during the period. Keybank National Association OH’s holdings in Tandem Diabetes Care were worth $245,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Brooklyn Investment Group acquired a new stake in shares of Tandem Diabetes Care during the third quarter worth $28,000. Assetmark Inc. bought a new position in Tandem Diabetes Care during the third quarter worth about $29,000. Jones Financial Companies Lllp lifted its holdings in Tandem Diabetes Care by 195.8% during the fourth quarter. Jones Financial Companies Lllp now owns 1,130 shares of the medical device company’s stock worth $41,000 after acquiring an additional 748 shares in the last quarter. McIlrath & Eck LLC bought a new position in Tandem Diabetes Care during the third quarter worth about $52,000. Finally, Smartleaf Asset Management LLC lifted its holdings in Tandem Diabetes Care by 163.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,775 shares of the medical device company’s stock worth $65,000 after acquiring an additional 1,101 shares in the last quarter.

Wall Street Analyst Weigh In

TNDM has been the topic of several recent analyst reports. Barclays reduced their target price on Tandem Diabetes Care from $60.00 to $53.00 and set an “overweight” rating on the stock in a report on Friday, February 28th. Canaccord Genuity Group reiterated a “buy” rating and set a $63.00 target price on shares of Tandem Diabetes Care in a report on Wednesday, February 26th. Royal Bank of Canada cut their price target on Tandem Diabetes Care from $65.00 to $55.00 and set an “outperform” rating on the stock in a report on Thursday, February 27th. Morgan Stanley lowered Tandem Diabetes Care from an “overweight” rating to an “equal weight” rating and cut their price target for the company from $45.00 to $22.00 in a report on Wednesday, March 5th. Finally, Robert W. Baird cut their price target on Tandem Diabetes Care from $37.00 to $33.00 and set a “neutral” rating on the stock in a report on Thursday, February 27th. Eight equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $45.38.

Tandem Diabetes Care Price Performance

NASDAQ:TNDM opened at $17.89 on Wednesday. The stock’s 50-day simple moving average is $32.43 and its 200 day simple moving average is $35.10. The company has a market cap of $1.19 billion, a P/E ratio of -9.27 and a beta of 1.45. The company has a debt-to-equity ratio of 1.29, a quick ratio of 2.32 and a current ratio of 2.90. Tandem Diabetes Care, Inc. has a 52-week low of $17.64 and a 52-week high of $53.69.

Insiders Place Their Bets

In other Tandem Diabetes Care news, COO Jean-Claude Kyrillos purchased 10,538 shares of the stock in a transaction on Friday, March 7th. The shares were purchased at an average price of $18.12 per share, with a total value of $190,948.56. Following the completion of the transaction, the chief operating officer now directly owns 10,538 shares in the company, valued at $190,948.56. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 2.20% of the company’s stock.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.